“When we asked colleagues at Pfizer to develop a vaccine against Covid-19 in less than a year, you did. When we asked you to quickly expand manufacturing so that we could produce 3.4 billion doses per year, you did, ”Bourla said. “Now we ask you to do something so important to educate yourself on the policies that will help our breakthroughs get into the hands of those who need them, while protecting our industry’s ability to develop those breakthroughs by. first place. “
He added that the company would share methods to raise awareness on the issue in the coming days.
The emailed video included a link titled “CLICK HERE to email your congressman today”. A disclaimer at the bottom of the page reads: “Participation in any Pfizer Grassroots mobilization is completely voluntary and is not a requirement of your employment with Pfizer. “
President Nancy Pelosi’s drug pricing plan HR 3 (117) would order the government to negotiate the prices of a set number of expensive drugs, a move the Congressional Budget Office says could save more than $ 450 billion dollars over 10 years. Congressional Democrats propose using project savings to pay for other party health care priorities, including over $ 300 billion Medicare expansion to include vision, dental and hearing care . But budget experts also predicted that price controls would bring eight fewer new drugs to market over 10 years and 30 fewer over the next decade.
Bourla’s call to action is the latest as pharmaceutical companies rally to fight drug price reforms proposed by Democrats. On September 15, the large industry lobby in Washington, PhRMA, released a letter signed by each member company that said manufacturers’ ability to innovate was “under attack.” The lobby launched a seven-figure television and web advertising campaign the same week, including ads in POLITICO.
Meanwhile, Democratic House leaders are moving forward with price negotiations in their social spending agenda despite dissent in their caucus. But Representative Scott Peters (D-Calif.), Who leads House opposition among Democrats, said this week he was buying a narrower version of the drug price negotiations from other lawmakers, including Arizona Senator Kyrsten Sinema, who advocated for a smaller package.
Pfizer and other drug companies have supported tougher measures to reduce drug prices, such as eliminating discounts they pay to drug benefit managers and capping out-of-pocket costs for patients. While the latter enjoys broad support, the former has an expected cost of nearly $ 200 billion that has also divided lawmakers.